177 related articles for article (PubMed ID: 11189097)
1. Minority recruitment in the prostate cancer prevention trial.
Moinpour CM; Atkinson JO; Thomas SM; Underwood SM; Harvey C; Parzuchowski J; Lovato LC; Ryan AM; Hill MS; Deantoni E; Gritz ER; Thompson IM; Coltman CA
Ann Epidemiol; 2000 Nov; 10(8 Suppl):S85-91. PubMed ID: 11189097
[TBL] [Abstract][Full Text] [Related]
2. Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.
Gohagan JK; Broski K; Gren LH; Fouad MN; Higgins D; Lappe K; Ogden S; Shambaugh V; Pinsky PF; O'Brien B; Yurgalevich S; Riley T; Wright P; Prorok PC
Rev Recent Clin Trials; 2015; 10(3):187-93. PubMed ID: 26435288
[TBL] [Abstract][Full Text] [Related]
3. PCPT update: enrollment mounts, but minority participation lags.
Reynolds T
J Natl Cancer Inst; 1994 Oct; 86(20):1500-1. PubMed ID: 7932802
[No Abstract] [Full Text] [Related]
4. Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial.
Cook ED; Arnold KB; Hermos JA; McCaskill-Stevens W; Moody-Thomas S; Probstfield JL; Hamilton SJ; Campbell RD; Anderson KB; Minasian LM
Clin Trials; 2010 Feb; 7(1):90-9. PubMed ID: 20156960
[TBL] [Abstract][Full Text] [Related]
5. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Cook ED; Moody-Thomas S; Anderson KB; Campbell R; Hamilton SJ; Harrington JM; Lippman SM; Minasian LM; Paskett ED; Craine S; Arnold KB; Probstfield JL
Clin Trials; 2005; 2(5):436-42. PubMed ID: 16315648
[TBL] [Abstract][Full Text] [Related]
6. Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors.
Moinpour CM; Lovato LC; Thompson IM; Ware JE; Ganz PA; Patrick DL; Shumaker SA; Donaldson GW; Ryan A; Coltman CA
J Clin Oncol; 2000 May; 18(9):1942-53. PubMed ID: 10784636
[TBL] [Abstract][Full Text] [Related]
7. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
8. The Prostate Cancer Prevention Trial: current status.
Higgins B; Thompson IM
J Urol; 2004 Feb; 171(2 Pt 2):S15-7; discussion S8. PubMed ID: 14713747
[TBL] [Abstract][Full Text] [Related]
9. Design of the Prostate Cancer Prevention Trial (PCPT).
Feigl P; Blumenstein B; Thompson I; Crowley J; Wolf M; Kramer BS; Coltman CA; Brawley OW; Ford LG
Control Clin Trials; 1995 Jun; 16(3):150-63. PubMed ID: 7540965
[TBL] [Abstract][Full Text] [Related]
10. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the Prostate Cancer Prevention Trial (PCPT).
Goodman PJ; Tangen CM; Crowley JJ; Carlin SM; Ryan A; Coltman CA; Ford LG; Thompson IM
Control Clin Trials; 2004 Apr; 25(2):203-22. PubMed ID: 15020037
[TBL] [Abstract][Full Text] [Related]
12. Impact and costs of targeted recruitment of minorities to the National Lung Screening Trial.
Duda C; Mahon I; Chen MH; Snyder B; Barr R; Chiles C; Falk R; Fishman EK; Gemmel D; Goldin JG; Brown K; Munden RF; Vydareny K; Aberle DR
Clin Trials; 2011 Apr; 8(2):214-23. PubMed ID: 21242173
[TBL] [Abstract][Full Text] [Related]
13. Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement.
Balakrishnan AS; Palmer NR; Fergus KB; Gaither TW; Baradaran N; Ndoye M; Breyer BN
J Urol; 2019 Feb; 201(2):259-267. PubMed ID: 30218761
[TBL] [Abstract][Full Text] [Related]
14. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
[TBL] [Abstract][Full Text] [Related]
15. Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
Eggly S; Hamel LM; Heath E; Manning MA; Albrecht TL; Barton E; Wojda M; Foster T; Carducci M; Lansey D; Wang T; Abdallah R; Abrahamian N; Kim S; Senft N; Penner LA
BMC Cancer; 2017 Dec; 17(1):807. PubMed ID: 29197371
[TBL] [Abstract][Full Text] [Related]
16. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA; Holzbeierlein JM
Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
[TBL] [Abstract][Full Text] [Related]
17. [The pathologist's perspective on the PCPT trial].
Molinié V; Allory Y
Prog Urol; 2008 Apr; 18 Suppl 3():S47-52. PubMed ID: 18455084
[TBL] [Abstract][Full Text] [Related]
18. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
19. Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review.
Strait A; Castillo F; Choden S; Li J; Whitaker E; Falasinnu T; Schmajuk G; Yazdany J
JAMA Netw Open; 2019 Nov; 2(11):e1914745. PubMed ID: 31722023
[TBL] [Abstract][Full Text] [Related]
20. Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.
Dew A; Khan S; Babinski C; Michel N; Heffernan M; Stephan S; Jordan N; Jovanovic B; Carney P; Bergan R
Clin Trials; 2013 Apr; 10(2):292-9. PubMed ID: 23321266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
